Skip to content

About
Chromatography
Drug Development
Investor relations (EN)
Investor relations (SE)
Latest news
Contact

Menu

About
Chromatography
Drug Development
Investor relations (EN)
Investor relations (SE)
Latest news
Contact

Aktien

Pressmeddelanden
Finansiella rapporter
Kalender
Presentationer
Aktien
Bolagsstyrning
Prenumerera

Pressmeddelanden
Finansiella rapporter
Kalender
Presentationer
Aktien
Bolagsstyrning
Prenumerera

Aktien

Read more:

Nanologicas aktie är sedan 29 mars, 2022 listad på Nasdaq Stockholm Main Market. Aktien handlas via banker och fondkommissionärer.

Kortnamnet är NICA och ISIN-koden är SE 0005454873. Totala antalet aktier uppgår till 36 146 142 aktier och aktiekapitalet uppgår till cirka 14 820 923 SEK med ett kvotvärde på 0,41 SEK.

Nanologica AB (publ)
Forskargatan 20 G
SE-151 36 Södertälje
Sweden

Email: info@nanologica.com
Tel: +46 (0)8 410 749 49

Subscribe

To subscribe to our press releases and financial reports, please enter your e-mail address. Tick the box to approve the subscription and accept our privacy policy:

Email

Acceptance

Yes, I want to subscribe.

About us

Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.

The company’s vision is to contribute to better and cheaper medicine through porous silica. In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the production costs at the manufacturers. In Drug Development, the company’s platform for inhalation is developed to give patients with severe lung diseases access to new or improved treatments.

© Nanologica 2023

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT